Treatment of lung metastasis from renal cell carcinoma with lymphokine-activated killer cells and interleukin-2.
Project/Area Number |
62480336
|
Research Category |
Grant-in-Aid for General Scientific Research (B)
|
Allocation Type | Single-year Grants |
Research Field |
Urology
|
Research Institution | Yamanashi Medical College |
Principal Investigator |
UENO Akira Yamanashi Medical College, Dept. of Urology, 医学部, 教授 (30010193)
|
Co-Investigator(Kenkyū-buntansha) |
KOMATSU Hideki Yamanashi Medical College, Dept. of Urology, 医学部, 助教授 (30167407)
TASAKA Kachio Yamanashi Medical College, Dept. of Immunology, 医学部, 助教授 (40093265)
|
Project Period (FY) |
1987 – 1988
|
Project Status |
Completed (Fiscal Year 1988)
|
Budget Amount *help |
¥6,000,000 (Direct Cost: ¥6,000,000)
Fiscal Year 1988: ¥2,000,000 (Direct Cost: ¥2,000,000)
Fiscal Year 1987: ¥4,000,000 (Direct Cost: ¥4,000,000)
|
Keywords | renal cell carcinoma / lung metastasis / adoptive immunotherapy / lymphokine-activated killer cell / lymphokine-activated killer cell / 腎癌 / LAK細胞 / インターロイキン2 |
Research Abstract |
The conditions to induce lymphokine-activated killer (LAK) cells were investigated at first. Concentrations of serum in culture media, 1, 2 and 5% had no effect on induced LAK activity. The best density of peripheral blood lymphocytes in culture bottle was 2x10^6/ml, and the most effective concentration of recombinant interleukin-2 (<@2r<@D2IL-2) to generate LAK cells was 3u/ml. Cytotoxicity against Daudi cell appeared on the second day of culture and reached a peak on the third day. There was no difference in induced LAK activity between standing and rolling culture. One patient with lung metastasis from renal cell carcinoma was treated with LAK cells and <@2r<@D2IL-2. LAK cells and <@D2r@>D2IL-2 were administered 11 times during 14 months, the first 2 times intravenously and 9 times via bronchial artery. The total number of LAK cells injected was 16.1x10<@D19@>D1 cells. Induced LAK activities gradually decreased and reached minimum at 6th treatment. From the 6th treatment plasma exchange was performed the day before administration of LAK cells. Induced LAK activities recovered from the 7th treatment. Despite these treatments the size of the metastatic lesion gradually increased.
|
Report
(3 results)
Research Products
(13 results)